E-LIB Suche - Ergebnisse für: Homicsko, K.

1

Response and Resistance to Trametinib in MAP2K1-Mutant Trip..:

Krebs, F.S ; Moura, B ; Missiaglia, E...
info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms24054520. , 2023

2

Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity res..:

Tichet, M ; Wullschleger, S ; Chryplewicz, A...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.immuni.2022.12.006. , 2023

Link: https://serval.unil.ch/n..

3

Deep and lasting response and acquired resistance to BRAFV6..:

Anchisi, S ; Wolfer, A ; Bisig, B...
info:eu-repo/semantics/altIdentifier/doi/10.1080/15384047.2023.2193116. , 2023

Link: https://serval.unil.ch/n..

4

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipi..:

Homicsko, K ; Dummer, R ; Hoeller, C...
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers14092300. , 2022

Link: https://serval.unil.ch/n..

5

Safety and Efficacy of Ipilimumab plus Nivolumab and Sequen..:

Aedo-Lopez, V ; Gérard, C.L ; Boughdad, S...
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers14051162. , 2022

Link: https://serval.unil.ch/n..

6

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipi..:

Homicsko, K ; Dummer, R ; Hoeller, C...
ARTN 2300. , 2022

Link: https://repository.icr.a..

7

Estimated Costs of the Ipilimumab-Nivolumab Therapy and Rel..:

Gautron Moura, B ; Gerard, C.L ; Testart, N...
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers15010031. , 2022

Link: https://serval.unil.ch/n..

8

First communication on the efficacy of combined 177Lutetium..:

Digklia, A ; Boughdad, S ; Homicsko, K...
info:eu-repo/semantics/altIdentifier/doi/10.1136/jitc-2022-005383. , 2022

Link: https://serval.unil.ch/n..

9

Late-onset and long-lasting immune-related adverse events f..:

Ghisoni, E ; Wicky, A ; Bouchaab, H...
https://boris.unibe.ch/160865/. , 2021

Link: https://boris.unibe.ch/1..

10

Ovarian cancer with high-level focal ERBB2 amplification re..:

Thouvenin, L ; Charrier, M ; Clement, S...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.gore.2021.100787. , 2021

Link: https://serval.unil.ch/n..

11

Late-onset and long-lasting immune-related adverse events f..:

Ghisoni E ; Wicky A ; Bouchaab H...
info:eu-repo/semantics/altIdentifier/pmid/33865201. , 2021

Link: http://hdl.handle.net/11..

12

Late-onset and long-lasting immune-related adverse events f..:

Ghisoni, E ; Wicky, A ; Bouchaab, H...
info:eu-repo/semantics/altIdentifier/pmid/33865201. , 2021

Link: http://hdl.handle.net/23..

13

Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48..:

Krebs, F.S ; Gérard, C ; Wicky, A...
info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms21218021. , 2020

Link: https://serval.unil.ch/n..

14

Mélanome localement avancé et métastatique : nouveautés [Lo..:

Huber, A ; Latifyan, S ; Nikolopoulou, A...
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2020.16.695.1092. , 2020

Link: https://serval.unil.ch/n..

15

Durable response to palbociclib and letrozole in ovarian ca..:

Frisone, D ; Charrier, M ; Clement, S...
info:eu-repo/semantics/altIdentifier/doi/10.1080/15384047.2019.1685291. , 2020

Link: https://serval.unil.ch/n..